instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Aortic stenosis'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Arteriovenous fistula site complication'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Arteriovenous fistula site haemorrhage'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Arteriovenous fistula site infection'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Arteriovenous fistula thrombosis'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Arteriovenous graft site infection'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Arteriovenous graft thrombosis'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Arthralgia'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Asthenia'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Asthma'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Atrial fibrillation'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Back pain'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bacteraemia'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blood loss anaemia'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bradycardia'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bronchitis'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cardiac arrest'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cardiac failure congestive'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cellulitis'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cerebrovascular accident'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Chronic obstructive pulmonary disease'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Clostridium difficile colitis'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Constipation'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Contusion'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Coronary artery disease'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cough'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Death'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Deep vein thrombosis'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Device related infection'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diabetic foot'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diabetic ketoacidosis'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diarrhoea'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diverticulitis'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dizziness'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dyspnoea'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Encephalopathy'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Face oedema'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fall'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Femur fracture'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fluid overload'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gangrene'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastric ulcer'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastroenteritis'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastrointestinal haemorrhage'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Headache'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hyperkalaemia'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypertension'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypertensive crisis'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypervolaemia'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypoglycaemia'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypotension'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypoxic-ischaemic encephalopathy'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Influenza'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Insomnia'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Iron deficiency'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Limb injury'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Mental status changes'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metabolic encephalopathy'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Muscle spasms'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Musculoskeletal chest pain'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Musculoskeletal pain'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Myocardial infarction'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nausea'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Non-cardiac chest pain'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Oedema peripheral'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Osteomyelitis'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pain in extremity'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pain'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Peripheral swelling'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pleural effusion'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonia aspiration'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonia'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pruritus'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pulmonary oedema'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pulseless electrical activity'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pyrexia'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Respiratory failure'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Seizure'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sepsis'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Septic shock'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Small intestinal obstruction'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Staphylococcal bacteraemia'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Staphylococcal sepsis'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Syncope'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tachycardia'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Upper gastrointestinal haemorrhage'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Upper respiratory tract infection'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Urinary tract infection'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vascular graft complication'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Viral upper respiratory tract infection'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vomiting'. | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | ERYTHROPOIETIN, IRON | DrugsGivenReaction | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
What was the administration route of drug 'ERYTHROPOIETIN'? | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | Parenteral | DrugAdministrationRoute | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
What was the administration route of drug 'IRON'? | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
What was the dosage of drug 'ERYTHROPOIETIN'? | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | UNK, 3 TIMES/WK | DrugDosageText | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
What was the outcome of reaction 'Death'? | A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhi... | Fatal | ReactionOutcome | CC BY-NC-ND | 34307977 | 19,376,624 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective for unapproved indication'. | Recurrence and Outcome of Anti-Glomerular Basement Membrane Glomerulonephritis After Kidney Transplantation.
Recurrence of anti-glomerular basement membrane (anti-GBM) glomerulonephritis in the kidney graft is a rare event, described in limited reports. The aim of this study was to evaluate, in a large cohort of patien... | AZATHIOPRINE, CYCLOPHOSPHAMIDE, METHYLPREDNISOLONE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC-ND | 34307983 | 20,029,990 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Recurrence and Outcome of Anti-Glomerular Basement Membrane Glomerulonephritis After Kidney Transplantation.
Recurrence of anti-glomerular basement membrane (anti-GBM) glomerulonephritis in the kidney graft is a rare event, described in limited reports. The aim of this study was to evaluate, in a large cohort of patien... | AZATHIOPRINE, CYCLOPHOSPHAMIDE, METHYLPREDNISOLONE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC-ND | 34307983 | 20,029,990 | 2021-07 |
What was the administration route of drug 'AZATHIOPRINE'? | Recurrence and Outcome of Anti-Glomerular Basement Membrane Glomerulonephritis After Kidney Transplantation.
Recurrence of anti-glomerular basement membrane (anti-GBM) glomerulonephritis in the kidney graft is a rare event, described in limited reports. The aim of this study was to evaluate, in a large cohort of patien... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 34307983 | 20,029,990 | 2021-07 |
What was the administration route of drug 'CYCLOPHOSPHAMIDE'? | Recurrence and Outcome of Anti-Glomerular Basement Membrane Glomerulonephritis After Kidney Transplantation.
Recurrence of anti-glomerular basement membrane (anti-GBM) glomerulonephritis in the kidney graft is a rare event, described in limited reports. The aim of this study was to evaluate, in a large cohort of patien... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34307983 | 20,029,990 | 2021-07 |
What was the administration route of drug 'METHYLPREDNISOLONE'? | Recurrence and Outcome of Anti-Glomerular Basement Membrane Glomerulonephritis After Kidney Transplantation.
Recurrence of anti-glomerular basement membrane (anti-GBM) glomerulonephritis in the kidney graft is a rare event, described in limited reports. The aim of this study was to evaluate, in a large cohort of patien... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34307983 | 20,029,990 | 2021-07 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.